Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Bayer's Ph III clinical trial of Nifurtimox in pediatric patients with Chagas Disease meets primary endpoint

biospectrumasiaMarch 15, 2019

Tag: Bayer , Clinical Trial , Nifurtimox

PharmaSources Customer Service